Patents by Inventor Soumen Paul

Soumen Paul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Establishing and Maintaining Stem Cells in an Undiffferentiated State
    Publication number: 20120270313
    Abstract: The present invention embraces compositions and methods for establishing and maintaining stem cells and inhibiting stem cell differentiation using a selective Protein Kinase C (PKC) inhibitor.
    Type: Application
    Filed: May 24, 2012
    Publication date: October 25, 2012
    Applicant: University of Kansas
    Inventors: Soumen Paul, Debasree Dutta, Soma Ray, Jeffrey Aube, Frank John Schoenen
  • Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
    Patent number: 8193235
    Abstract: The present invention embraces compositions and methods for establishing and maintaining stem cells and inhibiting stem cell differentiation using a selective Protein Kinase C (PKC) inhibitor.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: June 5, 2012
    Assignee: University of Kansas
    Inventors: Soumen Paul, Debasree Dutta, Soma Ray, Jeffrey Aube, Frank John Schoenen
  • Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
    Publication number: 20100317100
    Abstract: The present invention embraces compositions and methods for establishing and maintaining stem cells and inhibiting stem cell differentiation using a selective Protein Kinase C (PKC) inhibitor.
    Type: Application
    Filed: June 11, 2010
    Publication date: December 16, 2010
    Inventors: Soumen Paul, Debasree Dutta, Soma Ray, Jeffrey Aube, Frank John Schoenen
  • Compositions and methods for modulating angiogenesis
    Publication number: 20060281670
    Abstract: Methods and compositions for modulating angiogenesis are disclosed. Such modulation is made possible by the use of NK-B, NK-B analogs, NK receptor agonists and NK receptor antagonists to promote or inhibit angiogenesis. The method for modulating the angiogenic activity of cells comprises contacting cells capable of angiogenesis with an effective amount of NK-B, an NK-B analog, an NK receptor agonist or an NK receptor antagonist wherein the angiogenic activity of the cells is increased or decreased. The angiogenesis modulating compounds can be administered to alleviate and or prevent angiogenesis related diseases in patients, such as, for example, cancer, rheumatoid arthritis, macular degeneration, atherosclerosis, coronary artery disease, peripheral vascular disease, varicose veins and preeclampsia.
    Type: Application
    Filed: June 9, 2006
    Publication date: December 14, 2006
    Inventors: Emery Bresnick, Soumen Paul